Eun Soo Kim1, Kyeong Ok Kim2, Byung Ik Jang2, Eun Young Kim3, Yoo Jin Lee4, Hyun Seok Lee1, Seong Woo Jeon1, Hyun Jin Kim5, Sung Kook Kim6. 1. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kyungpook National University School of Medicine, 130 Dongdeok-ro, Jung-gu, Daegu, 700-721, Korea. 2. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea. 3. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea. 4. Division of Gastroenterology, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, Korea. 5. Division of Gastroenterology, Department of Internal Medicine, Gyeongsang National University School of Medicine, Changwon, Korea. 6. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kyungpook National University School of Medicine, 130 Dongdeok-ro, Jung-gu, Daegu, 700-721, Korea. dandy813@knu.ac.kr.
Abstract
BACKGROUND: Although colonoscopy preparation may cause symptom flares in patients with ulcerative colitis (UC), little is known about the standard preparation regimen in this population. AIM: We aimed to compare 4L polyethylene glycol (4L-PEG) with 2L polyethylene glycol plus ascorbic acid (2L-PEG-Asc) in quiescent UC patients. METHODS:Patients with inactive UC undergoing colonoscopy for surveillance or checkup of mucosal healing were prospectively enrolled at 5 tertiary hospitals. They were randomly assigned to 4L-PEG and 2L-PEG-Asc groups. The Boston Bowel Preparation Scale (BBPS) was used for the preparation quality. Symptoms were assessed using the Simple Clinical Colitis Activity Index (SCCAI) before colonoscopy, at 1 and 4 weeks after the procedure. RESULTS: Overall, 109 patients were included in the study (4L-PEG group 53, 2L-PEG-Asc group 56, the mean age at diagnosis 42.25 years, male 77). The quality of preparation was comparable between the groups (BBPS ≥ 6, 96.2 vs. 92.9%, p = 0.679). Although 26 patients (23.8%) had increased SCCAI scores within 4 weeks after colonoscopy, resulting in a medication dose-up or add-on in 3 patients (2.7%), the rise in scores was not different between the groups. No serious adverse events during preparation were observed in either group. However, the 2L-PEG-Asc group was more likely to be willing to repeat the preparation with the same agent than the 4L-PEG group (82.1 vs. 64.2%, respectively, p = 0.034). CONCLUSION: PEG-based regimens with different volumes are equally effective and safe in inactive UC patients. 2L-PEG-Asc is more acceptable in this population as indicated by the willingness for further usage.
RCT Entities:
BACKGROUND: Although colonoscopy preparation may cause symptom flares in patients with ulcerative colitis (UC), little is known about the standard preparation regimen in this population. AIM: We aimed to compare 4L polyethylene glycol (4L-PEG) with 2L polyethylene glycol plus ascorbic acid (2L-PEG-Asc) in quiescent UC patients. METHODS:Patients with inactive UC undergoing colonoscopy for surveillance or checkup of mucosal healing were prospectively enrolled at 5 tertiary hospitals. They were randomly assigned to 4L-PEG and 2L-PEG-Asc groups. The Boston Bowel Preparation Scale (BBPS) was used for the preparation quality. Symptoms were assessed using the Simple Clinical Colitis Activity Index (SCCAI) before colonoscopy, at 1 and 4 weeks after the procedure. RESULTS: Overall, 109 patients were included in the study (4L-PEG group 53, 2L-PEG-Asc group 56, the mean age at diagnosis 42.25 years, male 77). The quality of preparation was comparable between the groups (BBPS ≥ 6, 96.2 vs. 92.9%, p = 0.679). Although 26 patients (23.8%) had increased SCCAI scores within 4 weeks after colonoscopy, resulting in a medication dose-up or add-on in 3 patients (2.7%), the rise in scores was not different between the groups. No serious adverse events during preparation were observed in either group. However, the 2L-PEG-Asc group was more likely to be willing to repeat the preparation with the same agent than the 4L-PEG group (82.1 vs. 64.2%, respectively, p = 0.034). CONCLUSION:PEG-based regimens with different volumes are equally effective and safe in inactive UC patients. 2L-PEG-Asc is more acceptable in this population as indicated by the willingness for further usage.
Authors: Alain Bitton; Donald Buie; Robert Enns; Brian G Feagan; Jennifer L Jones; John K Marshall; Scott Whittaker; Anne M Griffiths; Remo Panaccione Journal: Am J Gastroenterol Date: 2011-11-22 Impact factor: 10.864
Authors: Dina Kao; Eoin Lalor; Gurpal Sandha; Richard N Fedorak; Bloeme van der Knoop; Stieneke Doornweerd; Harmke van Kooten; Eline Schreuders; William Midodzi; Sander Veldhuyzen van Zanten Journal: Can J Gastroenterol Date: 2011-12 Impact factor: 3.522
Authors: Maaike J Denters; Marthe Schreuder; Annekatrien C T M Depla; Rosalie C Mallant-Hent; Mariette C A van Kouwen; Marije Deutekom; Patrick M Bossuyt; Paul Fockens; Evelien Dekker Journal: Eur J Gastroenterol Hepatol Date: 2013-08 Impact factor: 2.566
Authors: Sophie Restellini; Omar Kherad; Talat Bessissow; Charles Ménard; Myriam Martel; Maryam Taheri Tanjani; Peter L Lakatos; Alan N Barkun Journal: World J Gastroenterol Date: 2017-08-28 Impact factor: 5.742
Authors: Andrea N Burnett-Hartman; Xinwei Hua; Tessa C Rue; Negar Golchin; Larry Kessler; Ali Rowhani-Rahbar Journal: PLoS One Date: 2019-01-09 Impact factor: 3.240
Authors: Milena Di Leo; Andrea Iannone; Monica Arena; Giuseppe Losurdo; Maria Angela Palamara; Giuseppe Iabichino; Pierluigi Consolo; Maria Rendina; Carmelo Luigiano; Alfredo Di Leo Journal: World J Gastroenterol Date: 2021-12-07 Impact factor: 5.742